Hyehyun Jeong
Overview
Explore the profile of Hyehyun Jeong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee Y, Yoo T, Lee S, Chung I, Kim H, Ko B, et al.
J Breast Cancer
. 2025 Mar;
28(1):11-22.
PMID: 40047087
Purpose: This study analyzed the pathological complete response (pCR) rates, long-term outcomes, and biological features of human epidermal growth factor receptor 2 (HER2)-zero, HER2-low, and HER2-positive breast cancer patients undergoing...
2.
Shin Y, Lee S, Jeong H, Ahn J, Jung K, Kim S, et al.
Cancer Res Treat
. 2025 Mar;
PMID: 40045569
Purpose: Although HER2 positivity is prevalent in microinvasive breast cancer (MIBC), data focused on HER2-positive MIBC are limited. We investigated the clinical course and long-term outcomes of HER2-positive MIBC and...
3.
Kim S, Jeong H, Kim S, Kim J, Hong Y, Kim D, et al.
Cancer Res Treat
. 2025 Jan;
PMID: 39810491
Purpose: To compare clinicopathologic features and clinical outcomes of metastatic colorectal cancer (mCRC) based on EGFR amplification status. Materials And Methods: Patients with mCRC who underwent next-generation sequencing using a...
4.
Jeong H, Ryu J, Jeong J, Han S, Hyung J, Ahn J, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39806206
Purpose: Estrogen receptor (ER) expression and heterogeneity affect endocrine therapy efficacy. F-fluoroestradiol (F-FES) PET/CT is an effective non-invasive method to analyze systemic ER expression. This study aimed to examine the...
5.
Yoo C, Jeong H, Jeong J, Kim K, Lee S, Ryoo B, et al.
J Hepatol
. 2024 Nov;
PMID: 39532185
Background & Aims: Surgery is the only curative therapeutic option for resectable extrahepatic cholangiocarcinoma, but recurrence is common, and prognosis is poor. There is an unmet clinical need for improved...
6.
Cho S, Lee Y, Huh G, Jeong H, Yoo C, Tae Jun S, et al.
Scand J Gastroenterol
. 2024 Oct;
59(12):1330-1335.
PMID: 39387458
Background And Aims: Pancreatic ductal adenocarcinoma (PDAC) often presents as acute pancreatitis (AP). However, data on the clinical outcomes of PDAC initially presenting as AP are limited. We aimed to...
7.
Ryu J, Hyung J, Han S, Jeong J, Lee S, Yoo T, et al.
J Nucl Med
. 2024 Oct;
65(11):1689-1694.
PMID: 39362758
The clinical impact of 16α-F-fluoro-17β-estradiol (F-FES) PET/CT on patient management has not been well investigated. The aim of this study was to assess the clinical impact of F-FES PET/CT on...
8.
Jeong H, Kim B, Lee C, Park I, Zang D, Choi H, et al.
Eur J Cancer
. 2024 Jul;
208:114194.
PMID: 38968872
Introduction: This multicenter phase I/IIa study aimed to determine the recommended phase II dose (RP2D) and evaluate the safety and preliminary efficacy of liposomal irinotecan (nal-IRI), oxaliplatin, and S-1 (NASOX)...
9.
Oh C, Jeong H, Kim W, Lee J, Song S, Song J, et al.
Int J Clin Oncol
. 2024 Mar;
29(6):853-861.
PMID: 38526622
Background: The real-world evidence about the efficacy of cytotoxic chemotherapy in desmoid tumors is still limited. We investigated the efficacy of chemotherapy in the treatment of recurrent or progressive desmoid...
10.
Yoon H, Shin Y, Ryoo B, Jeong H, Park I, Seo D, et al.
Pancreatology
. 2024 Feb;
24(3):424-430.
PMID: 38395676
Background: Modified FOLFIRINOX (mFOLFIRINOX) is one of the standard first-line therapies in borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC). However, there is no globally accepted...